Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 2 2Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × gedatolisib × Clear all
NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

NCT01925274 2019-01-08

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Pfizer

Phase 2 Terminated
19 enrolled 32 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡